US Regulators Approve First Fully Autonomous Blood-Drawing Robot

2026-08-21 hardware

Utrecht, Friday 21 August 2026
The US Food and Drug Administration has approved Vitestro’s autonomous robot, Aletta, offering a high-tech solution to ease severe healthcare staffing shortages by automating routine blood draws.

A Paradigm Shift in Phlebotomy

On 19 August 2026, the US Food and Drug Administration (FDA) granted marketing authorization through the de novo pathway to Vitestro’s Aletta [2][3][5]. This regulatory milestone establishes a brand-new category for robotic phlebotomy, representing the first standalone robotic device capable of performing venipuncture on adults in outpatient settings without hands-on clinical intervention [2][3][4]. The approval is highly timely, addressing a severe and growing shortage of trained phlebotomists across the United States [1][6]. While the device operates autonomously, it is designed to work under the supervision of a trained phlebotomy supervisor, who can oversee up to three Aletta devices simultaneously [2][3][6].

Advanced Imaging and Autonomous Precision

To ensure clinical accuracy and patient safety, Aletta integrates advanced multimodal imaging, combining near-infrared light with ultrasound technology to locate a suitable vein [1][3]. It also utilizes Doppler ultrasound to distinguish veins from arteries, ensuring the needle is only inserted when a safe pathway is identified [1][3][6]. Once a trained phlebotomist initiates the session, the patient positions their arm and starts the procedure by pressing a button [6]. From there, the robotic system autonomously executes the entire procedure, including applying the tourniquet, preparing the skin, inserting and disposing of the needle, changing collection tubes, and applying a bandage [3][6].

Clinical Efficacy and Safety Profile

The FDA’s decision was supported by extensive clinical data demonstrating that Aletta’s performance is comparable to, or in some cases better than, that of trained human phlebotomists [2][3][6]. In clinical trials, the device achieved a 94.5% first-stick success rate across a diverse patient population, including individuals with difficult venous access and varying skin tones [1][6]. Furthermore, 90% of study participants reported pain levels that were either lower than or similar to those experienced during a manual blood draw [1]. To protect patients, the system features continuous skin disinfection, professional cleaning protocols between sessions, and safety sensors that automatically detach the needle if excessive movement is detected [6].

Commercial Scaling and Financial Backing

Prior to securing US regulatory clearance, Vitestro’s blood-drawing technology had already been utilized on more than 10,000 patients worldwide and has been approved for use in Europe for the past two years [1][4]. The Utrecht-based medical robotics scale-up is well-positioned for its US market entry, having closed an oversubscribed $70 million Series B funding round in March 2026 [1]. This capital injection, backed by prominent investors including the Labcorp Venture Fund, Mayo Clinic, and Sutter Health, is earmarked for manufacturing scale-up, clinical expansion, and commercialization [1]. With US FDA clearance now secured, Vitestro is poised to scale its high-tech robotic hardware to meet the critical public health needs of the American healthcare system [1][6][GPT].

Sources & Ecosystem Partners

Regulatory approval Medical robotics